Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$130.69 USD

130.69
5,355,470

+0.76 (0.58%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $131.00 +0.31 (0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Insulet (PODD) Beats Earnings and Revenue Estimates in Q1

by Zacks Equity Research

Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.

Zacks Equity Research

Medidata (MDSO) Q1 Earnings Beat Estimates, Margins fall

by Zacks Equity Research

Medidata (MDSO) witnesses year-over-year revenue growth in double-digits across both operating segments in first-quarter 2019.

Zacks Equity Research

PRA Health (PRAH) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

PRA Health's (PRAH) Q1 earnings reflect top-line growth, favorable segmental performance and margin expansion.

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings Miss Mark, Margins Weak

by Zacks Equity Research

Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.

Zacks Equity Research

ResMed's (RMD) Q3 Earnings Beat Estimates, Revenues in Line

by Zacks Equity Research

ResMed (RMD) registers double-digit global revenue growth in Q3 on the back of solid sales from Software-as-a-Service businesses and new mask products plus devices.

Zacks Equity Research

Teleflex (TFX) Q1 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Teleflex (TFX) reports robust improvement in revenues on balanced growth across all segments and geographies.

Zacks Equity Research

Cardiovascular Systems (CSII) Q3 Earnings Top, View Tapered

by Zacks Equity Research

Cardiovascular Systems (CSII) rides high on a year-over-year rise in both Coronary and peripheral device revenues.

Zacks Equity Research

NuVasive (NUVA) Q1 Earnings Top Estimates, Margins Strong

by Zacks Equity Research

NuVasive's (NUVA) solid international sales in Q1 boost investor confidence in the stock.

Zacks Equity Research

DexCom (DXCM) Beats on Q1 Earnings, Hikes '19 Guidance

by Zacks Equity Research

DexCom's (DXCM) Q1 earnings gain from top-line growth and solid segmental performance. However, contraction in gross margin remains a headwind.

Zacks Equity Research

AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss

by Zacks Equity Research

AmerisourceBergen's (ABC) Q2 earnings gain from solid segmental performance and higher adjusted operating income growth. But contraction in adjusted gross and operating margins remains a dampener.

Zacks Equity Research

Amedisys (AMED) Tops Earnings and Revenue Estimates in Q1

by Zacks Equity Research

At Home Health and Hospice divisions, Amedisys (AMED) witnesses solid year-over-year growth in Medicare and non-Medicare revenues.

Zacks Equity Research

ABIOMED (ABMD) Q4 Earnings Meet Estimates, Sales Rise in Japan

by Zacks Equity Research

ABIOMED's (ABMD) Q4 results gain from solid Impella show in Japan.

Zacks Equity Research

Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.

Zacks Equity Research

CVS Health's (CVS) Q1 Earnings Top Estimates, EPS View Up

by Zacks Equity Research

Year-over-year growth in CVS Health's (CVS) top line is aided by a strong Pharmacy Services segment, benefiting from the upside in specialty services.

Zacks Equity Research

IDEXX (IDXX) Q1 Earnings Top Estimates, EPS Guidance Up

by Zacks Equity Research

Strong sales at the CAG business favor IDEXX's (IDXX) top line in Q1.

Zacks Equity Research

Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark

by Zacks Equity Research

Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.

Urmimala Biswas headshot

LabCorp (LH) Q1 Earnings Top Mark, Revenues Lag Estimates

by Urmimala Biswas

Despite increasing acquisitions and favorable mix, the disposition of certain businesses and the implementation of PAMA are adversely affecting LabCorp's (LH) growth.

Zacks Equity Research

Chemed (CHE) Q1 Earnings Miss Estimates, Revenues Grow Y/Y

by Zacks Equity Research

Despite several downsides, Chemed (CHE) witnesses solid revenue growth across key subsidiaries - VITAS and Roto-Rooter.

Zacks Equity Research

Ecolab (ECL) Earnings Beat, Revenues Miss Estimates in Q1

by Zacks Equity Research

Ecolab (ECL) gains from core Global Industrial and Global Institutional segments in Q1.

Zacks Equity Research

Hill-Rom's (HRC) Earnings and Revenues Top Estimates in Q2

by Zacks Equity Research

The strong Q2 performance of Hill-Rom (HRC) is backed by solid core revenue growth, continued margin expansion and strategic investments.

Zacks Equity Research

Top Ranked Income Stocks to Buy for April 29th

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 29th

Urmimala Biswas headshot

Zimmer Biomet's (ZBH) Q1 Earnings, Revenues Beat Estimates

by Urmimala Biswas

While sales in Americas remains dull, Zimmer Biomet (ZBH) is witnessing strength in the Asia Pacific and EMEA regions.

Zacks Equity Research

Integra LifeSciences (IART) Q1 Earnings Beat, Margins Rise

by Zacks Equity Research

Integra LifeSciences' (IART) quarterly performance is majorly hurt by the company's exit from the transition services agreements covering Western Europe.

Zacks Equity Research

Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.

Zacks Equity Research

GNC Holdings (GNC) Reports Q1 Earnings, Revenues Down Y/Y

by Zacks Equity Research

Despite year-over-year decline in earnings and revenues, better performing International segment and key developments favor GNC Holdings (GNC) in Q1.